Dr. Peter Gey's practice focuses on European and German antitrust and competition law, European state aid law and regulation, with emphasis on the pharmaceutical and agro-chemical industries and the life science sector.

Dr. Gey also has substantial experience in public procurement law, in particular in relation to tenders of German public health funds for pharmaceuticals and medical devices.

Professional Activities

Dr. Gey is a member of the Association for the Study of Antitrust Law (Studienvereinigung Kartellrecht) and the German-American Lawyers Association. He has lectured on German and European antitrust and competition law at the University of Applied Sciences Frankfurt and regularly publishes in the field of antitrust law and regulation. Dr. Gey is a former Scholar of Deutscher Akademischer Austauschdienst (DAAD).


  • Advice to an international pharma company in the European Commission’s sector inquiry in the pharma sector
  • Securing first phase German merger control clearance of for two acquisitions of a major seed company
  • Represented various pharma companies in litigation relating to tender procedures by German public health funds for so-called rebate agreements ("Rabattverträge"), inter alia winning the first injunction for a pharma company against the multi-billion Euro rebate contract tender for pharmaceuticals 2008/09 of the biggest German public health fund. The litigation led to landmark decisions concerning the legal assessment of such rebate agreement tenders, including decisions of the Higher Social Court of Stuttgart, the Federal Social Court and the Federal Civil Court
  • Part of the team that advised an international flat glass producer in the European Commission’s flat glass price fixing investigation
  • Part of the team that advised the State of Hessen in state aid procedures before the European Commission relating to the financing of the Hessische Staatsweingüter and the regional airport of Kassel-Calden


  • Dr. Peter Gey is consistently recommended by JUVE Handbuch for antitrust, most recently in the 2022/2023 edition (“extensive know-how in anti-trust damages,” – peer review, 2020).
  • Recognized in the Handelsblatt Best Lawyers® in Germany list consecutively from 2020 - 2025 for antitrust and competition law.
  • Received the Global Competition Review “GCR Litigation of the Year Award: Cartel Prosecution 2017” for client representation in the “Sugar Cartel” proceedings.
  • Received the Global Competition Review "GCR Matter of the Year Award 2016" for representing Lufthansa AG in the "Air Freight Cartel" proceedings.
  • JUVE Handbuch 2016/2017 lists Dr. Peter Gey as a highly recommended lawyer for state aid law.
  • Legal 500 Germany 2020 and 2022 recommends Dr. Peter Gey for state aid law.
  • Recommended by JUVE Handbuch 2014/2015 to 2016/2017 editions for health care/pharmaceutical and medical devices law. Clients commend Dr. Gey as having “deep understanding of the pharmaceutical industry, consequently providing excellent advice on complex EU legal issues” (2014/2015). Clients note Dr. Gey’s work for “(providing) greatest satisfaction” (2016/2017).
  • Legal 500 Germany has consistently recommended Dr. Peter Gey since 2015 for the pharmaceutical sector. Clients recognize Dr. Gey as having an “extremely deep understanding of the pharmaceutical industry” (2017).

Insights & News


  • Education

    • Second State Exam, Frankfurt Court of Appeals, 2005

    • PhD, Antitrust Law, University of Hamburg, 2004

      summa cum laude
    • LLM, University of Chicago Law School, 2001

    • First State Exam, University of Dresden, 1999

  • Admissions

    • Frankfurt

    • Brussels

  • Languages

    • English

    • German



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.